Company Profile
Tyra Biosciences Stock Price, News & Catalysts
- Ticker:
- TYRA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
20.24 USD (-3.30%)
Close
Last updated: October 6, 2026
1.7B USD
Market cap
Why the stock is moving
As of Oct 6, 2026, TYRA closed down 3.30% at $20.24. No new same-company headline was identified in the current news window.
Company overview
Precision Medicine Company Focused on FGFR Biology
Tyra Biosciences develops small-molecule medicines targeting fibroblast growth factor receptor alterations in cancer and skeletal disorders. Its programs are designed to improve target selectivity and enable treatment in earlier or chronic disease settings.
SNÃ…P Discovery Platform
The in-house SNÃ…P platform supports structure-based design of selective inhibitors intended to overcome limitations such as off-target toxicity, resistance mutations, and insufficient exposure.
Dabogratinib Lead Program
Dabogratinib is an oral FGFR3-selective inhibitor in Phase 2 development. TYRA is pursuing a three-indication strategy spanning low-grade upper-tract urothelial carcinoma, intermediate-risk non-muscle-invasive bladder cancer, and achondroplasia.
Three Phase 2 Studies
SURF303 evaluates dabogratinib in low-grade upper-tract urothelial carcinoma, SURF302 in FGFR3-altered intermediate-risk non-muscle-invasive bladder cancer, and BEACH301 in children with achondroplasia.
Additional FGFR Programs
The pipeline also includes TYRA-430 and TYRA-200 for other FGFR-driven cancers, together with discovery programs intended to extend the company's precision-medicine approach across FGFR biology.
Future catalysts
- Initial Phase 2 SURF302 results from both dabogratinib dose cohorts in September 2026.
- Initial BEACH301 safety-sentinel results from dose levels 1 through 5 by the end of the first quarter of 2027.
- Initial Phase 2 SURF303 results in 2027.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Tyra Biosciences (TYRA)?
Tyra Biosciences (TYRA) most recently closed at 20.24 USD, a -3.30% move versus the previous session.
What is the market cap of Tyra Biosciences (TYRA)?
Tyra Biosciences currently has a market capitalization of 1.7B USD on BioPharmSignal.
What does Tyra Biosciences do?
Precision Medicine Company Focused on FGFR Biology Tyra Biosciences develops small-molecule medicines targeting fibroblast growth factor receptor alterations in cancer and skeletal disorders. Its programs are designed to improve target selectivity and enable treatment in earlier or chronic disease settings. SNÃ…P Discovery Platform The in-house SNÃ…P platform...
On which exchange is TYRA stock listed?
Tyra Biosciences (TYRA) is associated with NASDAQ, United States, Biopharma.
What is TYRA-430?
Additional FGFR Programs The pipeline also includes TYRA-430 and TYRA-200 for other FGFR-driven cancers, together with discovery programs intended to extend the company's precision-medicine approach across FGFR biology.
Which conditions is Tyra Biosciences targeting with TYRA-430?
Tyra Biosciences is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Tyra Biosciences describe recent progress with TYRA-430?
Initial Phase 2 SURF302 results from both dabogratinib dose cohorts in September 2026. Initial BEACH301 safety-sentinel results from dose levels 1 through 5 by the end of the first quarter of 2027. Initial Phase 2 SURF303 results in 2027.
What is TYRA-200?
Additional FGFR Programs The pipeline also includes TYRA-430 and TYRA-200 for other FGFR-driven cancers, together with discovery programs intended to extend the company's precision-medicine approach across FGFR biology.